Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,599.55
    -1,582.29 (-3.15%)
     

  • CMC Crypto 200

    1,261.65
    -96.36 (-7.10%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

Nestle to study diet-disease link with biotech deal -WSJ

Reuters - UK Focus

Jan 8 (Reuters) - Nestle SA is set to enter a biotechnology partnership with Cellular Dynamics International (NasdaqGM: ICEL - news) (CDI) to study the relation between diet and disease, the Wall Street Journal reported.

The maker of Kit Kat chocolate bars and Maggi soups will take brain and liver cells from CDI to study the effect of nutrients found in foods, the Journal cited Emmanuel Baetge, director of the Nestle Institute of Health Sciences (Other OTC: HESG - news) , as saying in an interview. ()

Madison, Wisconsin-based CDI develops and manufactures human cells in industrial quantities to precise specifications for customers to research cellular therapeutics, among other uses.

Both companies are expected to announce the deal this week without disclosing the financial terms, the newspaper added.

Nestle (VTX: NESN.VX - news) and CDI could not be reached for comment outside regular business hours.